abstract |
The present invention relates to use of oxidised thymosin beta 4 in therapy, more particularly in the treatment of diseases or conditions associated with an inflammatory response or septic shock. The present invention also provides pharmaceutical formulations comprising oxidised thymosin beta 4 together with a suitable excipient. |